洋地黄强心甙类药已沿用200余年,长期以来是增强心肌收缩力的唯一药物。迄今在治疗非梗阻性快速心率的低排性心力衰竭病人中仍不失为有效药物。但此类药物其治疗剂量与中毒剂量非常接近,甚至重叠而易产生毒性反应,而且临床观察对慢性、顽固性心力衰竭此类药物常难以奏效,因而对其长期的正性肌力作用已引起怀疑。60年代以来逐渐出现一些非洋地黄强心甙的正性肌力药物用于临床,这些药物单用或与扩血管药物合用,尤其对一 Digitalis glycosides drugs have been used more than 200 years, has long been the only drug to enhance myocardial contractility. So far in the treatment of non-obstructive fast heart rate in patients with low-rank heart failure is still an effective drug. However, the therapeutic dose of such drugs is very close to the dose of poisoning, even overlapping and prone to toxic reactions, and clinical observation of chronic, refractory heart failure such drugs often difficult to work, so its long-term positive inotropic effect has been caused doubt. Since the 1960s, some inotropic agents of non-digitalis glycosides have gradually emerged for clinical use. These drugs are used singly or in combination with vasodilator drugs, especially for one